Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis

Marianne S. Muhlebach, Sonya L. Heltshe, Elena B. Popowitch, Melissa B. Miller, Valeria Thompson, Margaret Kloster, Thomas Ferkol, Wynton C. Hoover, Michael S. Schechter, Lisa Saiman, Daniel J. Weiner, Lynne Quittell, Michael Schechter, Michelle Howenstine, Wynton Hoover, Marianne Muhlebach

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Rationale: Methicillin-resistant Staphylococcus aureus (MRSA) prevalence continues to increase in patients with cystic fibrosis (CF) in the United States, reaching 26.5% in 2012. Approximately 30% of strains are SCCmec (staphylococcal cassette chromosome mec) IV type, frequently USA300, which in the general population have different genotypic and phenotypic features than SCCmec II type. Objectives: We hypothesized that risk factors for acquisition and outcomes in patients with CF differed for "health care-associated" (SCCmec II) versus "community-associated" (SCCmec IV)MRSAstrains. Methods: To determine the role of SCCmec type and Panton-Valentine leukocidin (PVL), MRSA isolates from patients not more than 18 years old at seven CF centers were typed and the association of potential risk factors and subsequent clinical course was assessed, using data provided by the CF Patient Registry. Measurements and Main Results: Participants with chronic MRSA (295) had typeable isolates and clinical data; 205 (69.5%) had SCCmec II PVL(-), 39 (13.2%) had SCCmec IV PVL(-), and 51 (17.3%) had SCCmec IVPVL(1) strains.SCCmec IV, comparedwith SCCmec II, increased during the study period, 1996-2010 (P = 0.03). SCCmec II was associated with Pseudomonas aeruginosa-positive cultures and three or more clinic visits in the 6 months preceding the first positive MRSA culture (adjusted odds ratio, 2.05; 95% confidence interval, 1.13-3.74; P = 0.019). Lung function and anthropometrics remained unchanged in the 6 months after initial MRSA detection compared with the 6 months prior. Although CF care increased for participants in both groups in the 6 months after MRSA detection, inhaled antibiotics were prescribed more frequently in those with SCCmec II strains and increased hospitalizations occurred in those with SCCmec IV PVL(-) strains compared with those with PVL(1) strains (adjusted difference, 34.10%; 95% confidence interval, 7.58-60.61; P = 0.012). Participants in both groups had an increase in CF care in the 2 years after MRSA detection compared with the 2 years prior. Conclusions: Increased exposure to CF clinics and P. aeruginosa may constitute risk factors for acquisition of SCCmec II MRSA strains. Clinical interventions increased 6 months and 2 years after initial MRSA detection regardless of SCCmec type.

Original languageEnglish (US)
Pages (from-to)864-871
Number of pages8
JournalAnnals of the American Thoracic Society
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Cystic Fibrosis
Multicenter Studies
Observational Studies
Chromosomes
Pseudomonas aeruginosa
Confidence Intervals
Ambulatory Care
Registries
Hospitalization
Odds Ratio

Keywords

  • Clinic visits
  • Methicillin-resistant Staphylococcus aureus
  • Panton-Valentine leukocidin
  • Risk factor
  • SCCmec type

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis. / Muhlebach, Marianne S.; Heltshe, Sonya L.; Popowitch, Elena B.; Miller, Melissa B.; Thompson, Valeria; Kloster, Margaret; Ferkol, Thomas; Hoover, Wynton C.; Schechter, Michael S.; Saiman, Lisa; Weiner, Daniel J.; Quittell, Lynne; Schechter, Michael; Howenstine, Michelle; Hoover, Wynton; Muhlebach, Marianne.

In: Annals of the American Thoracic Society, Vol. 12, No. 6, 01.06.2015, p. 864-871.

Research output: Contribution to journalArticle

Muhlebach, MS, Heltshe, SL, Popowitch, EB, Miller, MB, Thompson, V, Kloster, M, Ferkol, T, Hoover, WC, Schechter, MS, Saiman, L, Weiner, DJ, Quittell, L, Schechter, M, Howenstine, M, Hoover, W & Muhlebach, M 2015, 'Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis', Annals of the American Thoracic Society, vol. 12, no. 6, pp. 864-871. https://doi.org/10.1513/AnnalsATS.201412-596OC
Muhlebach, Marianne S. ; Heltshe, Sonya L. ; Popowitch, Elena B. ; Miller, Melissa B. ; Thompson, Valeria ; Kloster, Margaret ; Ferkol, Thomas ; Hoover, Wynton C. ; Schechter, Michael S. ; Saiman, Lisa ; Weiner, Daniel J. ; Quittell, Lynne ; Schechter, Michael ; Howenstine, Michelle ; Hoover, Wynton ; Muhlebach, Marianne. / Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis. In: Annals of the American Thoracic Society. 2015 ; Vol. 12, No. 6. pp. 864-871.
@article{0094d7620c594afbbeadeadd808ef3b6,
title = "Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis",
abstract = "Rationale: Methicillin-resistant Staphylococcus aureus (MRSA) prevalence continues to increase in patients with cystic fibrosis (CF) in the United States, reaching 26.5{\%} in 2012. Approximately 30{\%} of strains are SCCmec (staphylococcal cassette chromosome mec) IV type, frequently USA300, which in the general population have different genotypic and phenotypic features than SCCmec II type. Objectives: We hypothesized that risk factors for acquisition and outcomes in patients with CF differed for {"}health care-associated{"} (SCCmec II) versus {"}community-associated{"} (SCCmec IV)MRSAstrains. Methods: To determine the role of SCCmec type and Panton-Valentine leukocidin (PVL), MRSA isolates from patients not more than 18 years old at seven CF centers were typed and the association of potential risk factors and subsequent clinical course was assessed, using data provided by the CF Patient Registry. Measurements and Main Results: Participants with chronic MRSA (295) had typeable isolates and clinical data; 205 (69.5{\%}) had SCCmec II PVL(-), 39 (13.2{\%}) had SCCmec IV PVL(-), and 51 (17.3{\%}) had SCCmec IVPVL(1) strains.SCCmec IV, comparedwith SCCmec II, increased during the study period, 1996-2010 (P = 0.03). SCCmec II was associated with Pseudomonas aeruginosa-positive cultures and three or more clinic visits in the 6 months preceding the first positive MRSA culture (adjusted odds ratio, 2.05; 95{\%} confidence interval, 1.13-3.74; P = 0.019). Lung function and anthropometrics remained unchanged in the 6 months after initial MRSA detection compared with the 6 months prior. Although CF care increased for participants in both groups in the 6 months after MRSA detection, inhaled antibiotics were prescribed more frequently in those with SCCmec II strains and increased hospitalizations occurred in those with SCCmec IV PVL(-) strains compared with those with PVL(1) strains (adjusted difference, 34.10{\%}; 95{\%} confidence interval, 7.58-60.61; P = 0.012). Participants in both groups had an increase in CF care in the 2 years after MRSA detection compared with the 2 years prior. Conclusions: Increased exposure to CF clinics and P. aeruginosa may constitute risk factors for acquisition of SCCmec II MRSA strains. Clinical interventions increased 6 months and 2 years after initial MRSA detection regardless of SCCmec type.",
keywords = "Clinic visits, Methicillin-resistant Staphylococcus aureus, Panton-Valentine leukocidin, Risk factor, SCCmec type",
author = "Muhlebach, {Marianne S.} and Heltshe, {Sonya L.} and Popowitch, {Elena B.} and Miller, {Melissa B.} and Valeria Thompson and Margaret Kloster and Thomas Ferkol and Hoover, {Wynton C.} and Schechter, {Michael S.} and Lisa Saiman and Weiner, {Daniel J.} and Lynne Quittell and Michael Schechter and Michelle Howenstine and Wynton Hoover and Marianne Muhlebach",
year = "2015",
month = "6",
day = "1",
doi = "10.1513/AnnalsATS.201412-596OC",
language = "English (US)",
volume = "12",
pages = "864--871",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis

AU - Muhlebach, Marianne S.

AU - Heltshe, Sonya L.

AU - Popowitch, Elena B.

AU - Miller, Melissa B.

AU - Thompson, Valeria

AU - Kloster, Margaret

AU - Ferkol, Thomas

AU - Hoover, Wynton C.

AU - Schechter, Michael S.

AU - Saiman, Lisa

AU - Weiner, Daniel J.

AU - Quittell, Lynne

AU - Schechter, Michael

AU - Howenstine, Michelle

AU - Hoover, Wynton

AU - Muhlebach, Marianne

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Rationale: Methicillin-resistant Staphylococcus aureus (MRSA) prevalence continues to increase in patients with cystic fibrosis (CF) in the United States, reaching 26.5% in 2012. Approximately 30% of strains are SCCmec (staphylococcal cassette chromosome mec) IV type, frequently USA300, which in the general population have different genotypic and phenotypic features than SCCmec II type. Objectives: We hypothesized that risk factors for acquisition and outcomes in patients with CF differed for "health care-associated" (SCCmec II) versus "community-associated" (SCCmec IV)MRSAstrains. Methods: To determine the role of SCCmec type and Panton-Valentine leukocidin (PVL), MRSA isolates from patients not more than 18 years old at seven CF centers were typed and the association of potential risk factors and subsequent clinical course was assessed, using data provided by the CF Patient Registry. Measurements and Main Results: Participants with chronic MRSA (295) had typeable isolates and clinical data; 205 (69.5%) had SCCmec II PVL(-), 39 (13.2%) had SCCmec IV PVL(-), and 51 (17.3%) had SCCmec IVPVL(1) strains.SCCmec IV, comparedwith SCCmec II, increased during the study period, 1996-2010 (P = 0.03). SCCmec II was associated with Pseudomonas aeruginosa-positive cultures and three or more clinic visits in the 6 months preceding the first positive MRSA culture (adjusted odds ratio, 2.05; 95% confidence interval, 1.13-3.74; P = 0.019). Lung function and anthropometrics remained unchanged in the 6 months after initial MRSA detection compared with the 6 months prior. Although CF care increased for participants in both groups in the 6 months after MRSA detection, inhaled antibiotics were prescribed more frequently in those with SCCmec II strains and increased hospitalizations occurred in those with SCCmec IV PVL(-) strains compared with those with PVL(1) strains (adjusted difference, 34.10%; 95% confidence interval, 7.58-60.61; P = 0.012). Participants in both groups had an increase in CF care in the 2 years after MRSA detection compared with the 2 years prior. Conclusions: Increased exposure to CF clinics and P. aeruginosa may constitute risk factors for acquisition of SCCmec II MRSA strains. Clinical interventions increased 6 months and 2 years after initial MRSA detection regardless of SCCmec type.

AB - Rationale: Methicillin-resistant Staphylococcus aureus (MRSA) prevalence continues to increase in patients with cystic fibrosis (CF) in the United States, reaching 26.5% in 2012. Approximately 30% of strains are SCCmec (staphylococcal cassette chromosome mec) IV type, frequently USA300, which in the general population have different genotypic and phenotypic features than SCCmec II type. Objectives: We hypothesized that risk factors for acquisition and outcomes in patients with CF differed for "health care-associated" (SCCmec II) versus "community-associated" (SCCmec IV)MRSAstrains. Methods: To determine the role of SCCmec type and Panton-Valentine leukocidin (PVL), MRSA isolates from patients not more than 18 years old at seven CF centers were typed and the association of potential risk factors and subsequent clinical course was assessed, using data provided by the CF Patient Registry. Measurements and Main Results: Participants with chronic MRSA (295) had typeable isolates and clinical data; 205 (69.5%) had SCCmec II PVL(-), 39 (13.2%) had SCCmec IV PVL(-), and 51 (17.3%) had SCCmec IVPVL(1) strains.SCCmec IV, comparedwith SCCmec II, increased during the study period, 1996-2010 (P = 0.03). SCCmec II was associated with Pseudomonas aeruginosa-positive cultures and three or more clinic visits in the 6 months preceding the first positive MRSA culture (adjusted odds ratio, 2.05; 95% confidence interval, 1.13-3.74; P = 0.019). Lung function and anthropometrics remained unchanged in the 6 months after initial MRSA detection compared with the 6 months prior. Although CF care increased for participants in both groups in the 6 months after MRSA detection, inhaled antibiotics were prescribed more frequently in those with SCCmec II strains and increased hospitalizations occurred in those with SCCmec IV PVL(-) strains compared with those with PVL(1) strains (adjusted difference, 34.10%; 95% confidence interval, 7.58-60.61; P = 0.012). Participants in both groups had an increase in CF care in the 2 years after MRSA detection compared with the 2 years prior. Conclusions: Increased exposure to CF clinics and P. aeruginosa may constitute risk factors for acquisition of SCCmec II MRSA strains. Clinical interventions increased 6 months and 2 years after initial MRSA detection regardless of SCCmec type.

KW - Clinic visits

KW - Methicillin-resistant Staphylococcus aureus

KW - Panton-Valentine leukocidin

KW - Risk factor

KW - SCCmec type

UR - http://www.scopus.com/inward/record.url?scp=84942257215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942257215&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201412-596OC

DO - 10.1513/AnnalsATS.201412-596OC

M3 - Article

VL - 12

SP - 864

EP - 871

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 6

ER -